RE:RE:BioImmune ... Their path to Breakthrough designationMore treatments than our 2-doses treatment.
From the cllnical trial record:
Drug: N-803 and BCG BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction).
After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3.
Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.
Eligible patients have the option to receive maintenance treatment in the fourth treatment period at Months 24, 30, and 36.